tomorrow is end-of-quarter AND end-of-half window dressing: these BAC steps are useless in bringing down the flood of shares drowning this stock...who are you kidding? better than a bunch of nonsense you have posted. Tomorrow closing will be a great shorting opportunity most likely. What a bunch of bunk!
what's this nonsense of a so-called 50%raise of dividend to a MASSIVE $0.075 cents/share and a miserable buyback of only 5 million shares (up from 4 million)....this is absolute #$%$ imho.
thanks for elucidating the details further...however, I wouldn't go jumping up and down this early in the process -- hope this or any sale doesn't turn out to be a fire sale -- and Ihope Papa wasn't just brought on board to um, er, conclude matters.
1) I heard what I heard on Bloomberg.
2) I don't know where you are coming up with your name and figures, much less your conjecture about any potential outcome. Care to elucidate (at least provide a source)?
A little while ago (sometime between 2:30 - 3:00 EDT) I caught part of segment being broadcast on Bloomberg TV to the effect that Valeant has hired Goldman Sachs to find a buyer for one of Valeant's companies related to opioids -- didn't catch the name of the company or exact drug name, but this may be the reason for the strength in VRX this afternoon. FWIW
It's not "old" news...just filed it yesterday. MOREOVER, they reported they held an 8.8% Stake as of March 31, 2016...so, not only have they cut that stake almost in half since Ackman/Pershing became involved, they have clearly stepped up the pace of selling their stake.
From AF's tweetblog: Adam Feuerstein @adamfeuerstein 8h8 hours ago
"$SRPT -- today's development is good news, step towards eteplirsen approval. Confirms FDA & SRPT are compromising, working together."
you and others here keep saying you "hope" the Western Blot results give affirmative clarity -- this just goes to my point that all the hype around here is primarily from Hopiums and that you really have absolutely no idea of the scientific and other implications. So sorry.
For those jumping to the conclusion that today's announcement by Serepta means that "approval is imminent" and various other misinterpretations (and jumps to mis-conclusions) posted now and probably yet to to be pronounced by non-scientists and other speculators on this board are once again engaging in "HOPIUM" and I would venture that most on this board do not even understand what the FDA has requested from Serepta. You armchair "researchers" were wrong when you "presumed" an imminent favorable decision by the FDA when the FDA (again) delayed its decision on May 25th. Sorry, but your "hopium" is again misplaced. Nothing wrong with being hopeful, but to jump to the conclusions you prematurely jump to is as destructive and misplaced as are opinions on the other side of the coin.
Good luck with your hopium -- I hope you aren't disappointed (not just by the FDA response, but for all that will ensue down that yellow brick road thereafter.
so, who is going to pay for it, besides the exact same public taxpayers that currently pay for their medicaid coverage? You better hope Trump doesn't win.
Moreover, 1) How many patients could afford the $100,000 (mfrg cost) pricetag? 2) How many insurers are going to foot thebill realistically? Remember what it was like getting an insurer to pay for stem cell transplants (and in some cases, still is like pulling teeth, due to the efficacy/non-approved questions? Aren't more and more insurer's pulling out of Obamacare areas?
No doubt, this is an extraordinarily sad situation and difficult situation for EVERYONE and no matter what there will not likely be many winners, if any at all. jmo.
one way or the other. The delay is inexcusable and this agency, funded by US taxpayers should step up to the plate with their decision -- one way or the other -- once and for all.